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Tumors alter their microenvironment to promote survival using methods such as 
angiogenesis promotion, growth signals, and immune suppression. The immune system 
becomes unresponsive to transformed neoplastic cells through a variety of methods 
including T cell suppression, increased myeloid-derived suppressor cells (MDSCs), and 
reduced natural killer (NK) cell activity. NK cells have inherent killing capabilities and 
thus are among the first responders in recognizing and destroying abnormal cells. 
However, many types of cancers inhibit the surveillance and cytotoxic abilities of NK 
cells by releasing exosomes, vesicles that can modulate the tumor microenvironment 
(TME) and intercellular communication for the purpose of enhancing tumor malignancy. 
These 30-150 nm sized lipid bound vesicles are secreted by many cell types, including 
immune cells and tumor cells, and the specific protein, lipid, mRNA and miRNA 
contents contribute to the complex intercellular communication occurring between 
malignant and normal cells.  Cancer patients often have increased numbers of exosomes 
circulating through their body, including patients with hematological malignancies, such 
as lymphoma. The focus of this research was to determine the interactions between B cell 
lymphoma exosomes and NK cells, and characterize the resultant effects on NK cell 
xiv 
function. A specific objective of this research was to determine whether Survivin, an 
Inhibitor of Apoptosis protein recently found to be localized within exosomes, has a role 
in modulating NK cells similar to previous findings of T cell modulations.  We report that 
lymphoma exosomes have low levels of internalization into NK cells, and no detectable 
presence of immune modulating proteins MICA/B or TGF-β. Exposure of NK cells to 
lymphoma exosomes did not result in observable changes in degranulation or cytotoxic 
ability.  However, treatment with recombinant Survivin protein was able to decrease 
NKG2D receptor levels in NK cells stimulated with target cells, and decrease protein 
levels of TNF-α, IFN-γ, perforin, and Granzyme B. A better understanding of the 
underlying processes by which Survivin or exosomes suppress immune cells in the TME 
may pave the way to more efficacious immunological therapies against cancer.
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CHAPTER ONE 
PERIPHERAL BLOOD CELL INTERACTIONS WITH CANCER-DERIVED 
EXOSOMES AFFECT IMMUNE FUNCTION  
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Kabagwira, and Nathan R. Wall 
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Abstract 
Cancer-derived exosomes are constitutively produced and secreted into the blood 
and biofluids of their host patients providing a liquid biopsy for early detection and 
diagnosis.  Cancer exosomes influence biological mechanisms that are beneficial to the 
tumor cells where they are produced and the microenvironment in which these tumors 
exist.  Accumulating evidence suggests that exosomes transport proteins, lipids, DNA, 
mRNA, miRNA and long noncoding RNA (lncRNA) for the purpose of cell-cell and cell-
extracellular communication.  These exosomes consistently reflect the status as well as 
identity of their cell of origin and as such may conceivably be affecting the ability of a 
functional immune system to recognize and eliminate cancer cells.  Recognizing and 
mapping the pathways in which immune suppression is garnered through these tumor-
derived exosomes (TEX) may lead to treatment strategies in which specific cell 
membrane proteins or receptors may be targeted, allowing for immune surveillance to 
once again help with the treatment of cancer. This chapter focuses on how cancer 
exosomes interact with immune cells in the blood. 
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Exosomes are small 30-150 nm sized extracellular vesicles (EVs) important in the 
intercellular communication between cells(Thery et al., 2002, Ratajczak et al., 2006, Iero 
et al., 2008, Bobrie et al., 2012).  Communication can occur both by transfer of nucleic 
acids and proteins, or by binding cell-surface receptors and inducing cell signaling 
pathways(Feng et al., 2010, Kalluri, 2016).  Both normal and tumor cells release 
exosomes, although tumor derived exosomes (TEX) have been the subject of a wide 
range of studies.  TEX have been shown to be involved in many aspects of the tumor 
microenvironment (TME) including immune suppression(Thery et al., 2009, Zhang & 
Grizzle, 2011), antigen presentation(Wolfers et al., 2001, Mallegol et al., 2005, Hao et 
al., 2007, Zeelenberg et al., 2008, Zeelenberg et al., 2011), a means of acquiring 
chemotherapeutic resistance(Shedden et al., 2003, Safaei et al., 2005, Khan et al., 2009, 
Wang et al., 2014, Yu et al., 2016), as biomarker reservoirs(Skog et al., 2008, Taylor & 
Gercel-Taylor, 2008, Mitchell et al., 2009, Welton et al., 2010, Keller et al., 2011, Hong 
et al., 2014a, Turay et al., 2016), inducers of angiogenesis(Deregibus et al., 2007, 
Kawamoto et al., 2012, Kosaka et al., 2013), and vehicles of niche preparation for 
metastasis(Graves et al., 2004, Hood et al., 2011, Luga et al., 2012, Peinado et al., 2012, 
Suetsugu et al., 2013) (Figure 1).   However, modes and mechanisms of uptake are not 
completely understood.  Cells appear to internalize EVs through several endocytic 
pathways, including clathrin- and caveolin-dependent endocytosis, phagocytosis, and 
lipid raft–mediated internalization.  It is likely that cells utilize multiple routes to take up 
EVs, depending on the proteins, glycoproteins, and lipids found on the surface of the 
vesicles and the target cell itself(Mulcahy et al., 2014).  Numerous studies show   
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Figure 1.  Cancer Exosomes Influence the Tumor Microenvironment. Tumor-derived 
exosomes (TEX) function in favor of metastasis, support angiogenesis, confer 
chemoresistance and promote immune-suppression and cellular proliferation.  Exosomes 
from tumor cells were found to release functional biomolecules into the tumor 
microenvironment (TME) thereby affecting the biology of cancer. 
  
5 
proficient uptake of TEX by endothelial cells(Nazarenko et al., 2010, Rana et al., 2012, 
Paggetti et al., 2015), epithelial cells(Obregon et al., 2009), fibroblasts(Clayton et al., 
2004), myeloid precursors in bone marrow(Peinado et al., 2012, Paggetti et al., 2015), 
mesenchymal stem cells(Paggetti et al., 2015), and other tumor cells(Franzen et al., 
2014) (Figure 2). 
Cancer cell uptake of exosomes has been well documented and studies even show 
that TEX can preferentially associate with cancer cells(Parolini et al., 2009, Smyth et al., 
2014).  Multiple groups have demonstrated that labeled tumor exosomes can be taken up 
by tumor cells.  Endocytic pathways are utilized by ovarian cancer cells to internalize 
exosomes from the SKOV3 ovarian cancer cell line(Escrevente et al., 2011), by 
glioblastoma cells(Svensson et al., 2013), and by bladder cancer cells as demonstrated by 
dose and time dependent uptake of PKH26 labeled bladder exosomes(Franzen et al., 
2014).  Treatment with heparin can partially block the active and specific mechanism of 
uptake, implicating receptor-mediated endocytosis involving heparin sulfate 
proteoglycans (HSPGs)(Franzen et al., 2014).  HSPGs were also shown to be critical in 
the internalization of glioblastoma exosomes by glioblastoma cells(Christianson et al., 
2013).  Other tumor types have demonstrated exosome uptake, such as colorectal cancer 
exosomes into lung cancer cells(Chiba et al., 2012) and breast cancer exosomes into 
breast cancer cell lines(O’Brien et al., Riches et al., 2014), although mechanisms 
underlying the uptake were not addressed. 
Diffuse large B cell lymphoma (DLCL), an aggressive form of lymphoma 
representing over 40% of adult lymphoma patients, has not until recently been 
investigated. In an attempt to close the gap in knowledge concerning lymphoma TME  
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Figure 2.  Uptake of TEX by Cells in the Tumor Microenvironment.  Cancer cells release 
exosomes which are taken up by other cancer cells, endothelial cells, epithelial cells, 
fibroblasts, bone marrow myeloid precursor cells, and mesenchymal stem cells.  Exosomes 
from tumor cells were found to release functional biomolecules (protein, RNA, miRNA) 
into many cell types. 
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immunosuppression, normal human peripheral blood leukocytes were treated with 
PKH67-labeled lymphoma exosomes and monitored for uptake by measuring 
fluorescence at different time points using flow cytometry and fluorescent microscopy. 
Results show that of the four populations examined, B cells and monocytes demonstrated 
uptake of PKH67 labeled lymphoma exosomes, while T cells and NK cells displayed 
significantly less uptake(Ferguson Bennit et al., 2017).   
As TEX have exhibited multiple forms of influence within the immune system, 
immune cells have also been investigated regarding their ability to interact with 
exosomes.  Macrophages exhibit specialized capacity for internalizing exosomes, 
although they typically reside within tissue, not in circulation.  Their blood counterpart, 
monocytes, also appear to have a relatively high level of exosome internalization.  
Consequently, numerous investigations have focused on exosomal interactions with these 
myeloid-derived cell types.  Macrophages have been shown to internalize exosomes from 
both normal(Lässer et al., 2011) and malignant sources(Chow et al., 2014), with differing 
effects.  Macrophages exposed to breast cancer exosomes, but not normal exosomes, 
activated NF-B pathways and released pro-inflammatory cytokines like IL-6 and TNF-
α, possibly due to TLR2 interacting with palmitoylated protein ligands on the 
exosomes(Chow et al., 2014).  There are reports of multiple ways macrophages use to 
interact with exosomes, such as CD169 (SIAGLEC) to bind exosomes carrying sialic 
acids, as seen with B cell-derived exosomes expressing α2, 3-linked sialic 
acids(Saunderson et al., 2014).  Macrophages also utilize a dynamin-dependent 
phagocytic pathway to internalize vesicles(Barrès et al., 2010, Feng et al., 2010).  
Leukemia exosomes were found to be efficiently internalized via phagocytosis by 
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macrophages, while non-phagocytic cells such as T cells show few intracellular 
exosomes, with most interaction being with surface-attached vesicles(Feng et al., 2010). 
Monocytes also utilize phagocytic mechanisms to internalize exosomes, perhaps 
relying on tetraspanin targeting, as was shown by Rana et al(Rana et al., 2012).  Vesicle 
internalization by monocytes can induce changes such as production of cytokines like 
TNF-α, which has important downstream ramifications on T cells(Danesh et al., 2014).  
Like macrophages and monocytes, other cells of the myeloid lineage such as neutrophils 
and dendritic cells (DCs) have the ability for exosome uptake.  As one of the major 
infiltrators of the TME, neutrophil interactions with exosomes have been of interest.  
Investigations in leukemia demonstrate communication between tumor cells and 
neutrophils, transferring genomic DNAs (gDNAs) of the BCR/ABL hybrid gene from 
K562 cells to normal neutrophils(Cai et al., 2013) and even promoting leukemia 
tumorigenesis in rats(Cai et al., 2014). 
Early investigations in the exosome field recognized follicular DCs as interactors 
with exosomes(Morelli et al., 2004), and even though no specific receptors had been 
demonstrated yet, it seemed that alpha 4-integrin on B cell-derived exosomes was 
important(Wubbolts et al., 2003). Integrin complexes with CD9 and CD81 tetraspanins, 
externalized phosphatidylserine (PS), and CD11a (LFA-1)/ICAM-1 interactions all 
participate in the binding and uptake processes of DCs(Morelli et al., 2004, Segura et al., 
2007).  Uptake can be through endocytic mechanisms(Xie et al., 2010), including 
phagocytosis(Bastos-Amador et al., 2012) and DCs may be even more efficient than 
macrophages at picking up exosome-sized particles(Sheng et al., 2011, Czernek et al., 
2015). DCs are affected by their interactions with vesicles. Uptake of mast cell exosomes 
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can induce immature DCs to acquire antigen presenting capacity to T cells(Skokos et al., 
2003), and CD11b+ and CD11c+ cells in mice began releasing IL-6 and TNF-α and 
upregulated CD86 and MHC class II after exposure to exosomes(Sheng et al., 2011). 
Uptake of TEX by immature DCs can block maturation and promote induction of 
myeloid-derived suppressor cells(Yu et al., 2007, Xiang et al., 2009). 
In addition to antigen presenting cells (APCs) like macrophages and DCs, B cells 
are also capable of internalizing exosomes. B lymphocytes interact with exosomes 
containing MHC class II and ICAM-1 from mature DCs and acquire the ability to prime 
naïve T cells and trigger antigen-specific effector responses(Segura et al., 2005a, Segura 
et al., 2005b). B cells may need specific surface proteoglycans (HSPGs) such as 
syndecans and glypicans to aid exosome uptake. It was demonstrated that chronic 
lymphocytic leukemia (CLL) exosomes can be internalized via active uptake by various 
benign cell populations found in the TME such as endothelial cells, myeloid cells, bone 
marrow mesenchymal stem cells, and even some leukocytes. However, CLL B cells 
themselves did not show uptake of labelled exosomes – possibly due to a lack of surface 
HSPGs(Paggetti et al., 2015). In a separate study however, malignant B cell exosomes 
showed a natural specificity for B lymphocytes.  Mantle cell lymphoma (MCL) exosomes 
were efficiently internalized by both healthy and diseased B lymphocytes utilizing a 
cholesterol dependent pathway independent of clathrin and caveolin(Hazan-Halevy et al., 
2015). Very little uptake was recorded in bone marrow stroma cell lines, T cell leukemia 
cells, or NK cells.   
While effector cells such as T cells and NK cells are less equipped to internalize 
vesicles, there is still evidence for a variety of interactions with exosomes. T lymphocytes 
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are affected by exosomes from APCs harboring antigen in MHC class I and II molecules, 
and constitute an important aspect of immune system communication(Raposo et al., 
1996, Arnold & Mannie, 1999). The mechanisms of T cell internalization or binding of 
exosomes from APCs have been posited to involve the T cell receptor (TCR), CD28, and 
LFA-1 (CD11a)(Hwang & Ki, 2011). Activated T cells use LFA-1 (leukocyte function-
associated antigen-1) for binding of DC exosomes containing MHC class II(Nolte-'t Hoen 
et al., 2009).  This LFA-1/ICAM interaction is critical for priming of naïve T cells by 
exosomes from mature DCs(Segura et al., 2005a). CD4+ T cells can internalize DC 
exosomes and stimulate antigen-specific CD8+ CTL while overcoming Treg suppression, 
with a resultant shift in immune responses(Hao et al., 2007). In contrast to T cell priming 
effects of exosomes, tumor exosomes (TEX) can also suppress T cells. Surface ligands 
such as TGF-β1, TRAIL, PD-L1, FasL result in exosome-mediated cell death(Chen et al., 
2010, Stenqvist et al., 2013, Wang et al., 2016).  
Evidently, despite low exosome internalization, T cells are still subject to 
exosome-mediated effects. Likewise, even with little uptake, NK cells are influenced 
through exosomal interactions. NK cell cytotoxicity is frequently seen to be inhibited 
after exposure to exosomes derived from solid tumors and even EBV-immortalized B 
cells. It has been surmised that MICB and TGF-β1 expressed on exosomes are 
responsible(Clayton & Tabi, 2005, Clayton et al., 2008, Ashiru et al., 2010).  One 
mechanism is through the downregulation of NK activating receptor NKG2D, as 
exemplified by plasma exosomes from AML patients(Hong et al., 2014a). In contrast to 
TEX, DEX can promote NK activation and proliferation through copresentation of 
NKG2DL with IL-15Ra(Viaud et al., 2009). Some studies have found evidence of NK 
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cell uptake of exosomes in a time dependent fashion, perhaps utilizing PS located on 
vesicle membranes as demonstrated in ovarian cancer model(Keller et al., 2009). 
There have been few studies investigating uptake of exosomes by peripheral 
blood cell populations. In one study, rat pancreatic adenocarcinoma exosomes could be 
taken up by all leukocyte subpopulations examined, with CD11b+ cells demonstrating 
higher internalization than T or B cells(Zech et al., 2012). At this time there is only one 
other publication addressing peripheral blood uptake of lymphoma exosomes - a study by 
Hazan-Halevy et al., looking at MCL exosomes and their preferential uptake by B 
lymphocytes(Hazan-Halevy et al., 2015).  In this study, it was shown that exosomes 
isolated from a MCL cell line, when administered to B lymphocytes, NK cells, and 
various T lymphocytes, preferentially internalized into B lymphocytes.   
TEX have shown immunosuppressing properties and are involved in regulating 
peripheral tolerance in cancer patients. AML and solid tumor patients downregulated 
CD3 zeta and JAK3 expression in activated T cells(Taylor et al., 2003, Kim et al., 2006), 
mediated FasL apoptosis of CD8+ T cells(Huber et al., 2005, Kim et al., 2006), and 
promoted Treg conversion and proliferation(Wieckowski et al., 2009). After exposure to 
TEX, Tregs expressed IL-10, TGF-β1, CTLA-4, Granzyme B/perforin and had enhanced 
suppressor activity(Szajnik et al., 2010, Hong et al., 2014a). AML TEX were positive for 
TGF-β1 and could decrease NK cell cytotoxic activity, inducing Smad phosphorylation 
and NKG2D downregulation(Hong et al., 2014a, Hong et al., 2014b).  Another study 
investigating TEX from mesothelioma cells effect on lymphocyte responses to IL-2 
revealed inhibition of proliferation in all unfractionated lymphocytes, with CD4+ T cells 
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being most sensitive. Treg function was enhanced, while NK cell cytotoxic ability was 
directly inhibited, possibly through TGF-β1 dependent mechanisms(Clayton et al., 2007). 
Exosomes have been relatively well-studied in EBV-positive transformed human 
B cell lines, as these cells constitutively produce large numbers of MVBs and MHC class 
II molecules(Raposo et al., 1996, Escola et al., 1998, Dolcetti, 2015).  The WSU-DLCL2 
B cell lymphoma cell line used in our own study(Ferguson Bennit et al., 2017) as a 
source of exosomes, is EBV-free. This may be of interest because the virus has been 
known to hijack and alter exosomes in infected cells. The internalization and subsequent 
effects of these exosomes may involve viral factors, such as latent membrane protein 
(LMP). One group examined epithelial uptake of exosomes from EBV-infected B 
lymphocytes and found uptake was through a dynamin and caveolae-dependent process, 
and type III latency-derived exosomes were able to induce proliferation and upregulation 
of ICAM-1 in recipient cells(Nanbo et al., 2013).  LMP-1 was also harbored on 
exosomes from a Burkitt’s lymphoma cell line, and could mimic CD40 signaling to 
induce stimulatory changes in the B cells that efficiently bound them(Gutzeit et al., 
2014).  LMP-1 can also produce an immunosuppressive effect by inhibiting T cell 
proliferation and NK cytotoxicity(Dukers et al., 2000). Furthermore, EBV-infected cells 
can produce exosomes with FasL capable of inducing apoptosis in surrounding 
cells(Ahmed et al., 2015).  
Exosomes are important mediators and regulators of cellular communication.  
Although they are involved in active immunosuppression and can facilitate tumor 
progression, they are also a good source of tumor antigens.  Therefore, until a more full 
understanding of the interplay between the tumor microenvironment and the exosome 
13 
occurs, effective strategies to mobilize the immune system as an effective anticancer 
modality will be limited.  Recognizing the luminal and surface contents of the exosome is 
not enough to design exosome-associated therapy; understanding the communication 
patterns is also essential.  Moreover, identifying which exosome populations are 
communicating and which are providing additional ligands or receptors in order to 
facilitate communication will prove necessary to potentiate the immune response. 
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Abstract 
Exosomes are nano-sized lipid vesicles secreted into blood and other body fluids, 
and serve as vehicles for intercellular communication. Despite being an important 
component of the tumor microenvironment, exosomal targeting and uptake into recipient 
cells are still not fully understood. Few studies have looked at lymphoma exosomes and 
their interactions with circulating blood cells.  In this work we examine the exosomal 
uptake distribution among peripheral blood leukocytes (PBL) using vesicles derived from 
a diffuse large B cell lymphoma cell line, WSU-DLCL2.  Lymphoma cells survive, 
proliferate and are protected from the cytotoxic effects of chemotherapy agents by 
soluble factors or by direct contact with inflammatory and stromal cells within the tumor 
microenvironment (TME).  In an attempt to close the gap in knowledge concerning 
lymphoma TME immunosuppression, we have treated normal human peripheral blood 
leukocytes with PKH67-labeled lymphoma exosomes and monitored the uptake by 
measuring fluorescence at different time points using flow cytometry and fluorescent 
microscopy. Our results show that of the four populations examined, B cells and 
monocytes demonstrated uptake of PKH67 labeled exosomes, while T cells and NK cells 
displayed significantly less. 
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Introduction 
Diffuse large B cell lymphoma (DLCL) is an intermediate grade and the most 
common form of non-Hodgkin lymphoma (NHL), affecting 40-50% of adult lymphoma 
patients in the United States(Solimando et al., 2016).  Chemokines, cytokines, and 
growth factors are critical for the growth and survival of these malignant B 
cells(Grivennikov et al., 2010).  In addition, specific oncogenes such as c-Myc have been 
shown to have proliferation regulatory ability in malignant B cells both ex vivo and in 
vivo(Miller et al., 2012).  The cross talk between the tumor microenvironment and the 
DLCL cells is mainly mediated by direct cell-to-cell interactions but has recently been 
shown to be facilitated through extracellular vesicle trafficked soluble factors(Khan et al., 
2015, Valenzuela et al., 2015). 
Exosomes are small 30-150 nm sized extracellular vesicles important in the 
intercellular communication between cells (Thery et al., 2002, Ratajczak et al., 2006, Iero 
et al., 2008, Bobrie et al., 2012). Communication can occur both by transfer of nucleic 
acids and proteins, or by binding cell-surface receptors and inducing cell signaling 
pathways. Both normal and tumor cells release exosomes, although tumor-derived 
exosomes (TEX) have been the subject of a wide range of studies. TEX have been shown 
to be involved in many aspects of the TME including immune suppression (Thery et al., 
2009, Zhang & Grizzle, 2011), antigen presentation (Wolfers et al., 2001, Mallegol et al., 
2005, Hao et al., 2007, Zeelenberg et al., 2008, Zeelenberg et al., 2011), a means of 
acquiring chemotherapeutic resistance (Shedden et al., 2003, Safaei et al., 2005, Khan et 
al., 2009, Wang et al., 2014, Yu et al., 2016), as biomarker reservoirs (Skog et al., 2008, 
Taylor & Gercel-Taylor, 2008, Mitchell et al., 2009, Welton et al., 2010, Keller et al., 
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2011, Hong et al., 2014a, Turay et al., 2016), inducers of angiogenesis (Deregibus et al., 
2007, Kawamoto et al., 2012, Kosaka et al., 2013), and vehicles of niche preparation for 
metastasis (Graves et al., 2004, Hood et al., 2011, Luga et al., 2012, Peinado et al., 2012, 
Suetsugu et al., 2013).  
However, modes and mechanisms of uptake are not completely understood.  Cells 
appear to internalize exosomes through several endocytic pathways, including clathrin- 
and caveolin-dependent endocytosis, phagocytosis, and lipid raft–mediated 
internalization. It is likely that cells utilize multiple routes to take up exosomes, 
depending on the proteins, glycoproteins, and lipids found on the surface of the vesicles 
and target cell itself (Mulcahy et al., 2014). Numerous studies show proficient uptake of 
TEX by endothelial cells (Nazarenko et al., 2010, Rana et al., 2012, Paggetti et al., 
2015), epithelial cells (Obregon et al., 2009), fibroblasts (Clayton et al., 2004), myeloid 
precursors in bone marrow(Peinado et al., 2012, Paggetti et al., 2015), mesenchymal 
stem cells(Paggetti et al., 2015), and other tumor cells (Franzen et al., 2014). 
There have been few studies investigating uptake of exosomes by peripheral blood cell 
populations. Zech et al. found that rat pancreatic adenocarcinoma exosomes could be 
taken up by all leukocyte subpopulations examined, with CD11b+ cells demonstrating 
higher internalization than T or B cells(Zech et al., 2012). At this time there is only one 
other publication addressing peripheral blood uptake of lymphoma exosomes - a study by 
Hazan-Halevy et al. looking at MCL exosomes and their preferential uptake by B-
lymphocytes(Hazan-Halevy et al., 2015). Diffuse large B cell lymphoma (DLCL), an 
aggressive form of lymphoma representing over 40% of adult lymphoma patients, has not 
been investigated. It is therefore important to investigate these interactions between the 
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lymphoma cells and the TME in order to find and exploit new prognostic factors and to 
design new therapeutic approaches. 
 
Materials and Methods 
Cell Culture 
Human lymphoma cell lines WSU-DLCL2 and WSU-FSCCL were developed at 
Wayne State University and are EBV-negative(Al-Katib et al., 2009). Cell lines were 
grown in RPMI 1640 media supplemented with 10% USDA-sourced heat-inactivated 
fetal bovine serum (FBS) (Mediatech, Manassas, VA), 4 mM L-glutamine, 0.1 mg/ml 
streptomycin, and 100 units/ml penicillin and incubated at 37°C and 5% CO2.  Trypan 
blue staining was used to measure cell density (confluent at 1x106/ml) and viability 
(above 90%).  
Peripheral blood from healthy apheresis blood donors were obtained from the Life 
Stream Blood Bank (San Bernardino, CA) according to our approved Loma Linda 
University IRB protocols. The red blood cells were lysed using an ACK lysis buffer 
containing 8.3g/L NH4Cl, 1g/L KHCO3, and 1.8 ml 5% EDTA and centrifuged for 5 
minutes at 1,500 rpm at 4°C in a Beckman Coulter Allegra X-15R centrifuge, equipped 
with a SX4750 rotor to obtain a pellet of peripheral blood leukocytes (PBL). These were 
allowed to rest overnight before exosome treatment at 5x106/ml complete RPMI, with or 
without 100 IU/ml IL-2. This study, in its entirety, was approved by Loma Linda 
University’s institutional review board. 
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Exosome isolation 
Lymphoma cells were cultured for 24 hours in media depleted of exosomes from 
fetal bovine serum (FBS, Hyclone, Logan, UT) by overnight ultracentrifugation at 
100,000 x g. The cell conditioned medium (CM) was subjected to serial centrifugation, 
removing cells (300 × g, 5 min) and removing non-cellular debris (2000 × g for 10 min). 
The supernatant was then centrifuged at 10,000 × g for 30 min. Exosomes were isolated 
with the commercially available ExoQuick-TC™ (System Biosciences, Mountain View, 
CA) at a 1:5 ratio of reagent to CM and incubated overnight at 4°C.  A low speed spin at 
1500 x g for 30 minutes was sufficient to pellet the precipitated vesicles. Exosome pellets 
were resuspended in 40-70 μl PBS and protein quantified by BCA protein assay 
(Pierce/Thermo Scientific, Rockford, IL). Size of the vesicles was examined using 
dynamic light scattering (DLS) with a Nicomp N3000 nanoparticle sizing instrument 
(Particle Sizing Systems, Port Richey, FL).  
 
Uptake of Exosomes 
The exosome pellet, obtained from ExoQuick isolation, was labeled with PKH67 
Green Fluorescent Cell Linker Kit (Sigma Aldrich, St Louis, MO) as per manufacturer's 
protocol, with modifications.  Briefly, exosomes in PBS corresponding to 200 µg were 
added to 250 l of diluent C. As a control, the same volume of PBS was also added to 
250 l of diluent C (no exosome control) and processed in parallel. The exosome 
suspension was added to an equal volume of 2X PKH67 dye mixture, and mixed well for 
4 minutes. The dye reaction was stopped by addition of 9 ml of media depleted of bovine 
exosomes by ultracentrifugation and then spun for 90 minutes at 110,000 x g using an 
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SW41 rotor.  The pellet was washed in PBS with a second ultracentrifugation. The 
PKH67-labelled vesicles were incubated either with PBL for 1 hour, 4 hours, or 24 hours 
for dose –curve experiments or with NK cells for 30, 60, or 240 minutes. Cells were 
washed with PBS, stained with surface marker antibodies, and fixed in 2% 
paraformaldehyde before proceeding with further analysis by flow cytometry or 
microscopy. 
 
Flow Cytometry 
Antibodies directed against the following markers and directly labeled with 
indicated fluorophore were used to stain PBLs for flow cytometry analysis:  CD3-PE, 
CD1a-PE (Becton, Dickinson (BD) Biosciences, San Diego); CD14-APC (M5E2),) 
(BioLegend, San Diego, CA); CD56-APC (MY31, Tonbo Bioscience, San Diego, CA); 
and CD19-APC (H1B19). Live cell exosome binding was distinguished from dead cells 
using fixable viability dye eFluor 780 (eBioscience, Grand Island, NY).  Cells were run 
on MACSQuant Analyzer (Miltenyi Biotec, Auburn, CA) and data analyzed using 
FlowJo software (Tree Star, Ashland, OR).  The percentage of cells positive for PKH67+ 
exosomes was determined for each cell population. The gating strategies used to assess 
uptake of PKH67-labeled exosomes by leukocyte populations are shown in 
Supplementary Figures 2 and 3. 
 
Microscopy 
Samples were spun onto poly-L-lysine slides using StatSpin CytoFuge 2 
(Beckman Coulter) set at 800 rpm for 4 minutes. One drop of mounting medium 
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containing 4′,6-diamidino-2-phenylindole (DAPI) stain to visualize nuclear structures 
(Vectashield, Vector Laboratories, Burlingame CA) was placed onto the glass slide 
before adding glass coverslip and sealing with nail polish.  Slides were imaged using a 
fluorescence light microscope (Keyence BIOREVO BZ7000) and a Zeiss LSM 710 NLO 
confocal microscope. 
 
Statistical Analysis 
All the quantitative data of this study were expressed as the mean ± SD and 
statistical analysis was conducted using GraphPad Prism software v.5.01 for Windows 
(San Diego, CA). To test for statistical significance, nonparametric two-tailed Mann–
Whitney analysis was performed.  Comparisons between groups were performed using 
student’s t-test with probability p <0.05 considered to indicate a statistically significant 
difference. Each experiment was repeated at least twice to assess the level of 
reproducibility. 
 
Results 
Cellular Uptake Characterization of DLCL2 Exosomes 
Exosome uptake by peripheral blood cells was measured using flow cytometry 
and fluorescent microscopy, with demonstrated uptake differing between cell lineages 
and in a dose and time dependent manner. Specifically, to study the uptake of lymphoma-
derived exosomes by peripheral blood leukocytes, vesicles were isolated from the 
conditioned media from the WSU-DLCL2 cell line. Vesicle size was evaluated by 
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dynamic light scattering (DLS) and confirmed to be consistently in the reported range of 
exosomes (30-150 nm) (Supplementary Figure 1). 
The exosomes were labeled with a lipophilic dye, PKH67 after which 25, 50, 100, 
200 or 400 µg of these exosomes were incubated with peripheral blood leukocytes 
(PBLs) for 1, 4 and 24 hours. Internalization by confocal microscopy was performed and 
analyzed.  Exosomal internalization was observed as early as 1 hour post incubation with 
longer incubation times and higher concentrations resulting in higher accumulation of 
exosomes inside the cells (Figure 1). 
To study the kinetics of exosome accumulation, we performed quantitative flow 
cytometry.  PKH67 labeled DLCL2-exosomes were incubated with PBLs and the 
fluorescence intensity was detected.  Uptake was most prominent by B cells and myeloid-
derived cells and less so in T cells and NK cells (Figure 2). The uptake of exosomes 
from healthy B cells was rapid in the higher exosome concentrations, with 28% positive 
after 1 hour at 400 g/ml (Figure 2A and 2B) and increasing to 69% at 24 hours at 400 
g/ml (Figure 2B). Cell specificity for uptake of DLCL2-derived exosomes was further 
studied in a single experiment using B cells (CD19+), T cells (CD3+), NK cells (CD56+)  
and monocytes (CD14+) (Figure 2C).  Compared to B cells where 28% to 70% of cells 
showed exosome uptake in the 400 g/ml exosomes over the 24 hour study, NK cells, 
monocytes and T cells only maximized 6, 8 and 3 % uptake respectively (Figure 2C). 
After a second independent experiment was concluded, CD19+ B cells and CD14+  
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Figure 1.  Peripheral blood leukocytes take up DLCL2 exosomes.  Peripheral blood 
leukocytes were treated with DLCL2 exosomes (25-400 µg/ml) and harvested at 1, 4, and 
24 hours. Cells were cytospun onto poly-L-lysine coated slides. Microscopy images 
acquired with BIOREVO BZ7000 fluorescent microscope (Keyence), 20X magnification. 
Nucleic acids are stained with DAPI (blue), and exosome bind and internalization is 
visualized with PKH67 (green). Cells without the addition of exosomes were used as a 
negative control. Several fields were analyzed for each labeling condition, and 
representative results are presented. The data are representative of two independent 
experiments.  
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Figure 2.  Uptake of PKH67 labeled exosomes in a time- and dose-dependent manner. 
DLCL2 exosomes were labeled with PKH67 and then added to peripheral blood cells for 
various lengths of time (1, 4, and 24 hours) and treatment amounts (25, 50, 100, 200 and 
400 ug/ml). As measured by flow cytometry, the uptake of labeled exosomes proceeded in 
a time- and dose-dependent fashion. A.) Uptake of PKH67 labeled exosomes after 4 hours 
by CD19-APC cells (red).  Microscopy images acquired with Zeiss LSM 710 NLO 
confocal microscope. 60X magnification.  B.) Representative flow cytometry data of 
CD19+ cells.  C.) Graphical representation of the percentage of PKH+ cells in each of the 
four lineages derived from one donor: B cells (CD19+), monocytes (CD14+), NK cells 
(CD56+), and T cells (CD3+). D.) Combined data from two separate experiments depicting 
the disparity in uptake between each cell population. Results are expressed as mean ± SD. 
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monocytes maximized near 40% in the 400 g/ml incubation while CD3+ T cells and CD 
56+ NK cells only proved to be able to uptake near 10% (Figure 2D). 
The specificity of DLCL2 exosomes was further tested using exosomes derived 
from FSCCL and HeLa cells.  Co-culture of B cells and NK cells with 200 g/ml PKH67 
labeled DLCL2, FSCCL and HeLa-derived exosomes for 1 hour and 4 hour time points 
showed very similar results as were previously recorded using DLCL2 exosome (Figure 
3).  In this study B cells were able to rapidly and preferentially take up PKH67 stained 
DLCL2, FSCCL and HeLa cell derived exosomes in a time dependent manner while the 
NK cells were significantly less capable of this internalization. Four hours post 
incubation, 22% ±8, 20% ± 10, and 12% ± 9 of B cells had taken up DLCL2, FSCCL and 
HeLa exosomes respectively (Figure 3). 
 
Discussion 
Although the spleen, liver and lymph nodes take up the majority of exosomes 
produced by organs and hematopoietic cells, plasma and other body fluids still contain 
large quantities of exosomes(Srinivasan et al., 2016). Cancer cells in particular secrete 
large quantities of TEX, which can be found in peripherally circulating blood(Sun & Liu, 
2014). Consequently, blood cells are exposed to many exosomes from both normal and 
malignant cells(De Toro et al., 2015), which play key roles in modulating the immune 
system(Iero et al., 2008).  While previous studies have investigated exosomal interactions 
with leukocytes in lymphoid organs, such as antigen presenting cells (APCs) in the 
spleen(Morelli et al., 2004) and follicular dendritic cells (DCs) in the lymph  
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Figure 3.  Differences in uptake by NK cells and B cells is not unique to DLCL2 
exosomes.  DLCL2, FSCCL and HeLa cell-derived exosomes were labeled with 
PKH67 and then added to peripheral blood for 1 and 4 hours at 200 µg/ml. As 
measured by flow cytometry, the uptake of labeled exosomes proceeded in a time- and 
dose-dependent fashion as before in lymphocyte lineage B cells but not the NK cells. 
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nodes(Denzer et al., 2000, Wubbolts et al., 2003), there is less work done regarding 
uptake of exosomes by peripheral blood cell populations.  
In this study, we tested the hypothesis that some populations of white blood cells 
will be more receptive to interacting with B cell lymphoma exosomes, and therefore will 
be more vulnerable to tumor microenvironment modulating effects of these vesicles. In 
an attempt to close the gap in knowledge concerning lymphoma TME 
immunosuppression, we have treated normal human PBLs with PKH67-labeled 
lymphoma exosomes and monitored uptake by measuring fluorescence at different time 
points using flow cytometry and fluorescent microscopy. We expected to observe a 
disparity in exosome uptake between blood cells of lymphoid and myeloid lineages that 
we hypothesized was perhaps due to myeloid derived cells such as monocytes and 
macrophages, being better equipped for exosome uptake than lymphocytes such as B 
cells, T cells, and NK cells.  However, this was not what we observed with B cells being 
the most effective and efficient at TEX uptake. 
Our data is not consistent with previous studies, which show a disparity in uptake 
between myeloid derived cells and lymphocytes(Zech et al., 2012, Danesh et al., 2014). 
We demonstrated that NK and T cells have lower levels of internalization than 
monocytes and B cells. In our study model, B cells showed a high level of uptake, 
possibly due to the B cell origin of the lymphoma exosomes, supporting the idea of 
uptake specificity given the exosomes were collected primarily from cells originating 
from B cell lymphoma disease. These findings are in line with those of Hazan-Halevy et 
al.(Hazan-Halevy et al., 2015) and Gutzeit et al.(Gutzeit et al., 2014) concerning B cells 
and Riches et al. in their work with breast tissue(Riches et al., 2014).  In this study, we 
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observed that DLCL2 exosomes were taken up rapidly and preferentially into CD19+ B 
lymphocytes and CD14+ monocytes. Only a small percentage of T cells and NK cells 
showed internalization or binding to exosomes, even after 24 hour incubations.  We 
further investigated if the origin of the exosome would influence the preference or rate of 
uptake on the peripheral cell (Figure 3). Exosomes were taken from two lymphoma cell 
lines (DLCL2 and FSCCL) and from the cervical cancer cell line HeLa.  In our hands 
there was little difference recorded in exosomal uptake.  This may indicate that the 
uptake is controlled by something specific to the exosome rather than the cell of origin.  
The mechanisms of uptake into B lymphocytes remain to be elucidated, whether it 
be caveolin, clathrin, cholesterol, lipid-raft, or receptor-mediated endocytosis, or 
something completely novel and not proposed. In this work we have demonstrated a 
natural preference of TEXs to B cells, further supporting the concept of targeting therapy 
to this lymphocyte population. However, to fully appreciate and dissect the mechanism, 
many more cell line-derived as well as patient procured exosomes, from varying 
pathologies will need to be investigated, a process that has only just begun in our 
laboratory. By understanding the structure and marker/receptor profiles on the exosome, 
the cell of origin as well as the recipient cell’s membranes as well as the protein, RNA 
and DNA contents from within the exosome will further the ability to regulate the role of 
the TEX in the pathobiology of hematologic malignancies and to identify novel 
therapeutic approaches. 
In addition to the indirect effects of exosomes through interactions with APCs, 
and the limited ability of NK cells and T cells for exosome uptake, these cell populations 
seem to have a wide variety of responses to direct exposure to exosomes.  Whether these 
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responses are the result of surface interactions rather than uptake, or due to secondary 
effects from other cells which more readily internalize exosomes is not always apparent. 
There has been evidence for both possibilities, and it is likely that exosomes interacting 
with lymphocytes deliver signals by direct surface contact more frequently than 
internalization(Clayton et al., 2004, Hwang & Ki, 2011). The surface interactions 
between exosomes and recipient cells can occur via membrane-bound activating or 
inhibitory proteins which directly signal through relevant receptors and initiating 
downstream pathways.  TEXs are enriched in proteins specialized for surface 
interactions, such as integrins, MHC class I and II molecules, co-stimulatory molecules 
(CD40, CD86), various growth factor receptors, such as EGFR (epidermal growth factor 
receptor) or HER-2 (human epidermal growth factor receptor 2), death receptor ligands 
such as FasL (Fas ligand), TRAIL (tumor-necrosis-factor-related apoptosis-inducing 
ligand) or PD-L1 (programmed cell death ligand 1) and inhibitory factors such as PGE2 
(prostaglandin E2).  Therefore uptake is not necessary for a cell to be altered by 
exosomes, and may likely be the case for changes induced by exosomes in T cells and 
NK cells. In fact, much of the immune suppression mediated by TEX occur through 
surface molecules such as FasL, TGF-β1, and IL-10(Szajnik et al., 2010, Szczepanski et 
al., 2011, Whiteside, 2013). 
Perhaps an equally important aspect could be that exosome uptake have 
downstream direct and indirect effects on PBLs. Through producing cytokines like TNF-
α, presenting antigen on MHC I and II, and providing co-stimulatory signals via 
CD80/CD86 and CD40(Skokos et al., 2003, Danesh et al., 2014), many of the exosomal 
effects observed in T and NK cells may be an indirect result from primary changes 
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induced in macrophages, monocytes, B cells, and DCs which actually internalize the 
vesicles.  Uptake of exosomes induce monocytes to produce TNF-α(Danesh et al., 2014), 
macrophages and DCs capture and present antigen to T cells(Skokos et al., 2003), and B 
cells can be activated by antigen-carrying exosomes with subsequent Th1 cell 
stimulation(Qazi et al., 2009).  Antigen-bearing TEX seem to require uptake and 
processing by DCs before they can efficiently stimulate a specific CTL response(Wolfers 
et al., 2001, Dai et al., 2005). The exosomes from DCs carry MHC I, MHC II, CD80 and 
CD86, and are therefore equipped to elicit T cell activation through surface 
interactions(Viaud et al., 2010).  
To summarize, in the present study, we characterized DLCL2 cell line derived 
exosomes on different PBL populations showing that there is preference of targeted 
uptake.  However, it is still not clear whether exosomes are still inducing cellular 
signaling pathways in the T cell and NK cells through direct cell to cell contact.  From 
these findings, we hope a better understanding of tumor cell/TME communication may 
result, further leading to increased knowledge of how the tumor cells communicates with 
and manipulates the TME.  Through understanding these signaling pathways, we may 
better prepare therapeutic modalities to enhance immune cell surveillance and killing of 
these tumors which up to now seem immune. 
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Supplementary Figure 1.  Size Distribution of WSU-DLCL2 Exosomes. Number-weight 
distribution of EV size using dynamic light scattering (DLS) analysis with Nicomp BZ3000 
instrument.  Sample was read every minute for 30 minutes, with a calculated average 
diameter of 117 nm. One representative diameter histogram is shown. 
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Supplementary Figure 2. Gating Strategy to Assess Binding of PKH67-labeled Exosomes 
to PBL Populations. Antibodies specific to human T cells (CD3+), NK cells (CD56+), B 
cells (CD19+), and monocytes (CD14+) were used to identify populations within the 
peripheral blood leukocytes (PBLs). One representative dot plot is shown from two 
independent experiments 
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Supplementary Figure 3.  Internalization of PKH67-labeled exosomes by healthy PBL.  
Leukocytes were assayed by flow cytometry using specific antibodies to B Lymphocytes 
(APC-anti-CD19), T lymphocytes (PerCP-anti-CD3), NK cells (PE-anti-CD56) and 
monocytes (PeCy7-anti-CD14). Representative dot plots are shown for each cell 
population. 
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Abstract 
Natural killer (NK) cells have inherent abilities to kill target cells and are among 
the first responders in recognizing and destroying infected or transformed cells. However, 
many types of cancers inhibit the surveillance and cytotoxic abilities of NK cells by 
releasing exosomes, vesicles that can modulate the tumor microenvironment and 
intercellular communication for the purpose of enhancing tumor malignancy. Recently, 
cancer cell exosomes have been found to contain Survivin, an inhibitor of apoptosis 
(IAP) protein that prevents cell death and decreases immune response of lymphocytes. 
The purpose of this study is to explore the effect of Survivin and lymphoma-derived 
exosomes, which contain Survivin, on the immune functions of NK cells, such as the 
production and release of cytokines and cytotoxic granules. NK cells were obtained from 
the peripheral blood of healthy donors, and treated with pure Survivin protein, or 
exosomes from two lymphoma cell lines, DLCL2 and FSCCL. RNA was isolated from 
NK cell samples for measurement by PCR, and intracellular flow cytometry was used to 
determine protein expression. Degranulation capacity, cytotoxicity, and levels of NK cell 
activating receptor NKG2D were also assessed. Lymphoma exosomes were examined for 
size and protein content. This study established these lymphoma exosomes contained 
Survivin and FasL, but were negative for MICA/B and TGF-β.  Treatment with exosomes 
did not significantly alter NK cell functionality, but extracellular Survivin was seen to 
decrease NKG2D levels and the intracellular protein levels of perforin, Granzyme B, 
TNF-α and IFN-γ. 
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Introduction 
The active role of the tumor microenvironment (TME) in tumor pathogenesis has 
recently been gaining intense scrutiny as it can be responsible for delivering signals for 
clonal expansion, drug resistance, metastatic migration, and immune modulation.  Cancer 
development is not an autonomous process but depends on surrounding non-malignant 
components such as fibroblasts, microvasculature, stroma, mesenchymal cells, and 
immune cells. Interaction between tumors and their surrounding environment occurs via 
direct contact, soluble factors, and material exchange. One method that has received 
much interest in the preceding decade is small bilayer lipid vesicles known as exosomes, 
or more generally, as extracellular vesicles (EVs). These endosomally derived 30-150 nm 
vesicles contain proteins, lipids, and nucleic acids like miRNA, mRNA (Ratajczak et al., 
2006, Valadi et al., 2007), and even DNA (Cai et al., 2014, Kahlert et al., 2014) that can 
be sent into the extracellular environment and delivered to recipient cells either locally or 
systemically. Most tissue and immune cell types have been shown to produce exosomes, 
but tumor cells seem to produce increased numbers (Kim et al., 2005, Taylor & Gercel-
Taylor, 2008, Ohno et al., 2013, Turay et al., 2016). These tumor-derived exosomes 
(TEX) have a myriad of effects within the TME and beyond, with resulting enhanced 
malignant potential, niche preparation for metastasis, and angiogenesis (Peinado et al., 
2012, Rak & Guha, 2012). Importantly, TEX can have many influences on immune cells, 
resulting in both activation and suppression of tumor immunity (Clayton et al., 2007, 
Clayton et al., 2008, Bu et al., 2011, Taylor & Gercel-Taylor, 2011, Filipazzi et al., 
2012).   
Natural killer (NK) cells are important in the surveillance and eradication of 
virally infected and malignantly transformed cells, and are susceptible to suppression in 
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the TME (Fernández-Messina et al., 2010, Wada et al., 2010). TEX carrying ligands such 
as FasL, TGF-β, IL-10 and NKG2DL are implicated in the downregulation of T cell and 
NK cell activity (Andreola et al., 2002, Raffaghello et al., 2004, Clayton & Tabi, 2005, 
Huber et al., 2005, Bianco et al., 2007, Yoshimura & Muto, 2011). As NK cells form the 
first line of defense and are ready to kill without prior activation, their function is critical 
to controlling spontaneous tumorigenesis of epithelial and lymphoid malignancies 
(Smyth et al., 2000, Guerra et al., 2008). NK cell activation is based on a complex 
interplay of their inhibitory and activating receptors. Healthy cells display MHC class I 
proteins on their surface which bind to inhibitory KIRs (Killer-cell Immunoglobulin-like 
receptor) on NK cells to prevent activation.  Stressed cells often lose MHC class I and 
upregulate ligands such as MICA/B (MHC class I-related chains [MIC] A/B) and ULBPs 
(UL16 binding proteins) which bind to activating receptor NKG2D (Natural Killer Group 
2D receptor) (Lanier, 2008, Brenner et al., 2010, Belting et al., 2015).  Ligand binding 
stimulates downstream signaling to activate cytokine production of IFN-γ and TNF-α, 
and degranulation to release cytolytic proteins such as perforin and Granzyme B.  These 
proteins initiate apoptosis in the target cell by opening pores in the target cell membranes 
and cleaving cellular proteins.  The cytolytic functionality of NK cells can be inhibited by 
TEX through decreased release of perforin (Liu et al., 2006) and overexposure to soluble 
MICA/B with subsequent downregulation of the NKG2D receptor (Clayton & Tabi, 
2005, Oppenheim et al., 2005, Clayton et al., 2008, Chitadze et al., 2013, Reiners et al., 
2013).  
Exosomes as a vehicle for immune suppression can act through multiple 
modalities, such as surface ligands like FasL, PD-L1, and TGF-β, and content such as 
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miRNAs and proteins (Whiteside, 2017). In our lab, we discovered tumor-derived 
exosomes contain Survivin (Khan et al., 2011, Valenzuela et al., 2015), an anti-apoptotic 
protein that is generally found in the cytoplasm, mitochondria and nucleus of cancer cells 
(Fortugno et al., 2002). When this cancer-specific member of the Inhibitor of Apoptosis 
(IAP) family of proteins is found in the extracellular compartment, we have shown 
evidence of increased resistance to treatment, invasive potential, and proliferative 
capacity in surrounding cells (Khan et al., 2009). Additionally, extracellular Survivin can 
act upon T cells to skew their behavior towards Th2 and decrease CD8+ T cell activity 
(Jutzy et al., 2013). It is unclear whether other immune cell populations, such as NK 
cells, are also able to be affected by Survivin or exosomes from lymphoma cells. In this 
study, we investigate the influence of exosomes from lymphoma cell lines and Survivin 
on NK cell function. Our results indicate that conditioning of NK cells by extracellular 
Survivin-containing exosomes had little effect on NKG2D receptor levels, degranulation 
capacity, or cytolytic potential. However, while mRNA levels of NK cell proteins were 
not consistently affected, protein levels of IFN-γ, TNF-α, Perforin and Granzyme B were 
decreased as a result of treatment with recombinant Survivin protein. 
 
Materials and Methods 
Cell Culture 
Human lymphoma cell lines WSU-DLCL2 and WSU-FSCCL were a kind gift 
from Dr. Ayad Al-Katib at Wayne State University (Detroit, MI)(Al-Katib et al., 2009). 
Cell lines were grown in RPMI 1640 media supplemented with 10% USDA-sourced 
heat-inactivated fetal bovine serum (FBS) (Mediatech, Manassas, VA), 4 mM L-
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glutamine, 0.1 mg/ml streptomycin, and 100 units/ml penicillin and incubated at 37°C 
and 5% CO2.  Trypan blue staining was used to measure cell density (confluent at 
1X106/ml) and viability (above 90%).  
 
NK Cell Isolation and Culture 
Natural killer (NK) cells were prepared from freshly collected plasma apheresis 
peripheral blood obtained from healthy donors at the Life Stream Blood Bank (San 
Bernardino, CA), in accordance to LLU IRB protocols.  Peripheral blood was prepared as 
described previously (Ferguson Bennit et al., 2017).  NK cells were obtained from the 
total lymphocyte fraction by negative immunomagnetic cell separation using either 
EasySep or RosetteSep negative selection kit (STEMCELL, Vancouver, BC) or MACS 
magnetic NK Cell Isolation kit (Miltenyi Biotec, Auburn, CA). The purity of the NK cell 
population was determined by flow cytometric analysis and ranged from 85-95%, with all 
kits showing comparable performance in obtaining CD3-/CD56+ NK cells (greater than 
90% purity and viability).  NK cells were cultured at a high density of 5 × 106 cells/well 
in 6-well non-pyrogenic polystyrene culture plates overnight in RPMI 1640 media 
(Mediatech Inc. Manassas, VA, USA), supplemented with 10% FBS (Hyclone, Logan, 
UT), 1 mM L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, and 100 U/ml 
human recombinant IL-2 before use in experiments. 
 
Exosome Isolation 
Lymphoma cells were cultured for 24-48 hours in media depleted of exosomes 
from fetal bovine serum (FBS, Hyclone, Logan, UT) by overnight ultracentrifugation at 
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100,000 x g. Exosomes were isolated using previously described methods (Valenzuela et 
al., 2015) from conditioned medium after serial centrifugation with commercially 
available ExoQuick-TC™ (System Biosciences, Mountain View, CA). Exosome pellets 
were resuspended in 40-70 μl PBS and either used immediately for experiments or stored 
at −80˚C. The quantity of exosomal protein was determined by BCA protein assay 
(Pierce/Thermo Scientific, Rockford, IL).  The size and concentration of exosomes 
isolated using ExoQuick was determined using nanoparticle tracking analysis (NTA) with 
a NanoSight NS300 instrument (NanoSight, Malvern Instruments Ltd, Malvern, UK).  
Samples were diluted 1:100 in PBS.  Five sequential measurements of 60 seconds each 
were recorded at a flow rate of 20 µl/minute. The instrument was set to a detection 
threshold of 8 and 25 frames per second. Analysis was performed on software NTA 3.2 
Dev Build 3.2.16. 
 
Flow Cytometry Antibodies 
Antibodies and other reagents used were: Intracellular Fixation and 
Permeabilization Buffer kit, fixable viability dye e-Fluor 780, CD56 PerCP-eFluor 710, 
MICA/B Alexa Fluor 488, CD69 PE-Cy7 (eBioscience, Grand Island, NY); CD16 PE, 
CD56 PE (BD Biosciences, San Jose, CA); CD3 FITC, IFN-γ PE-Vio770, TNF-α PE-
Vio770, CD107a FITC (Miltenyi Biotec, Auburn, CA); CD3 PE-Cy7, CD3 FITC, CD56 
APC (MY31) (Tonbo Bioscience, San Diego, CA); Perforin Pacific Blue, Granzyme B 
Pacific Blue, NKG2D APC (BioLegend, San Diego, CA); Survivin Alexa Fluor 647 (Cell 
Signaling Technology, Danvers, MA). Data was collected on a Miltenyi MACSQuant 
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Analyzer flow cytometer (Miltenyi Biotec, Auburn, CA) and analyzed using FlowJo 
v10.0.8p software (Tree Star, Ashland, OR). 
 
Flow Cytometry Analysis of Exosomes 
Purified exosomes (200 μg) were incubated with 10 μl of 4-μm-diameter 
aldehyde/sulfate latex beads (Invitrogen, Eugene, OR) in PBS for one hour at room 
temperature with gentle agitation. After washing with PBS, samples were blocked with 
200 mM glycine for 30 minutes, and washed again. Beads were incubated with the 
following antibodies for 30 minutes: anti–CD63 (Millipore, Billerica, MA), anti-CD9 
(BD Biosciences, San Jose, CA), anti-HLA-A,B,C (BioLegend, San Diego, CA), anti-
TSG101 (Santa Cruz Biotechnology, Santa Cruz, CA), anti-HSP70 (Novus Biologicals, 
Littleton, CO), anti-LAMP-1 (Miltenyi Biotec, Auburn, CA), anti-MICA/B (eBioscience, 
Grand Island, NY), anti-CD81 (ProSci, Fort Collins, CO), anti-TGF-β (Peprotech, Rocky 
Hill, NJ), anti-FasL (Boster, Pleasanton, CA).  Staining with secondary antibodies for 30 
minutes followed, using goat-anti-rabbit Alexa Fluor 488 (Invitrogen, Euguene, OR) and 
goat-anti-mouse FITC (Becton Dickinson, Franklin Lakes, NJ). A “bead-only” control, as 
well as isotype-matched antibody controls were also prepared. Samples were washed 
twice, fixed with 1% paraformaldehyde and analyzed using a MACSQuant Analyzer and 
FlowJo software. Single beads were gated for fluorescence analysis. 
 
Degranulation Assay 
NK cell degranulation was evaluated by staining for CD107a (LAMP-1) during 
NK cell stimulation. Briefly, peripheral blood mononuclear cells (PBMCs) were treated 
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for 24 hours either with or without IL-2 (100 U/ml) and exposed to either 0, 0.1, or 1.0 
µg/ml of recombinant Survivin (Abcam, Cambridge, MA). Cells were then incubated in 
96-well round bottom plates for 6 hours with PMA (10 ng/well) and Ionomycin (50 
ng/well) as a positive control for activation, K562 cells (5X105/well) for targeted 
stimulation, or media as a negative control. Monensin (3 µM, Sigma Aldrich, St. Louis, 
MO) was added after the first hour to inhibit Golgi transport and prevent both release of 
cytokines (for intracellular detection) and to prevent acidification of endocytosed vesicles 
containing CD107a antibody. The anti-CD107a-FITC antibody (Miltenyi Biotec, Auburn, 
CA) or isotype control were added before NK cells were stimulated to allow binding to 
the degranulation marker as granules were exocytosed. Surface and intracellular staining 
was performed prior to flow cytometry, and analysis performed on the CD3-/CD56+ 
gated population.  
 
NKG2D Receptor Expression 
PBMCs obtained from healthy volunteers were co-incubated with isolated 
exosomes or Survivin to determine the percentage of NK cells (CD3-/CD56+) expressing 
the natural cytotoxicity receptor NKG2D on the cell surface, as previously described 
(Hong 2014). Briefly, PBMCs were activated with IL-2 alone or with additional 
stimulation of PMA/Ionomycin or K562 cells and co-incubated with exosomes (10 µg 
protein/ml) or Survivin (0-1 µg/ml) for 24 h at 37°C.  Cells were then stained with APC-
conjugated NKG2D antibody (BioLegend, San Diego, CA) and run on a MACSQuant 
flow cytometer (Miltenyi Biotec, Auburn, CA). The frequency of NKG2D+ cells were 
measured from the gated CD3-/CD56+ NK cells. The data are expressed as %NKG2D+ 
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cells/total CD3-CD56+ cells. The mean fluorescence intensity (MFI) of NKG2D on NK 
cells was also recorded. PBMC incubated in medium without exosomes were used as 
controls.  
 
Cytotoxicity Assay 
To determine cell-specific killing capacity of NK cells, the release of cytoplasmic 
lactate dehydrogenase (LDH) from lysed target K562 (erythroleukemia) cells was 
measured using the CytoTox 96 Non-Radioactive Cytotoxicity Assay (Promega, 
Fitchburg, WI), according to the manufacturer’s instructions. Briefly, NK cells isolated 
from healthy donors were incubated overnight at 5X106/ml in complete RPMI1640 media 
with 100 IU/ml IL-2. NK cells were then treated for 24 hour with either 10 µg/ml 
Survivin protein (Abcam, Cambridge, MA), exosomes from lymphoma cells (10-50 µg 
/ml), or media for control. A range of effector to target ratios from 20:1, 10:1, 5:1, 2.5:1, 
1.25:1, 0.625:1 were used, and the target K562 cells were added at 10,000 cells/well. 
After four hours of incubation at 37°C, the LDH containing media was transferred to a 
separate plate and absorbance read at 490 nm with a Bio-Tek µQuant microplate reader.  
The percentage of specific lysis was calculated according to a standard equation, specific 
lysis (%) = (experimental release – effector spontaneous release – target spontaneous 
release)/(target maximum release – target spontaneous release) X 100.  
  
Western Blot 
Western blotting was performed as previously described (Valenzuela et al., 2015). 
Membranes were immunostained using the following antibodies: rabbit polyclonal anti-
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Survivin (1:500-1000, Novus Biologicals, Littleton, CO); rabbit monoclonal anti-XIAP, 
anti-cIAP1, anti-cIAP2, rabbit polyclonal anti-β-actin (1:500-1000, Cell Signaling 
Technology, Danvers, MA); mouse polyclonal anti-LAMP-1 (1:500, BioLegend, San 
Diego, CA); mouse monoclonal anti-Granzyme B (OriGene, Rockville, MD); and rabbit 
polyclonal anti-Perforin (Boster, Pleasanton, CA).  Goat anti-mouse and goat anti-rabbit 
Dylight 800 secondary antibodies (Thermo Scientific, Waltham, MA) were used at a 
1:10,000 dilution. Immunoreactive bands were detected using the Odyssey imaging 
system (LI-COR Biosciences, Lincoln, NE). β-actin or LAMP-1 were used as loading 
controls for either cell lysates or exosomal protein, respectively. 
  
PCR 
Perforin, Granzyme B, TNF-α and IFN-γ mRNA expression was evaluated by 
PCR from magnetically sorted NK cells treated either with Survivin protein or 
lymphoma-derived exosomes or an untreated control. Cells were resuspended in 500 µL 
TRI Reagent Solution (Ambion, Grand Island, NY) and RNA was extracted according to 
the manufacturer’s protocol. RNA concentration was measured using Nanodrop 2000c 
(Thermo Fisher Scientific, Waltham, MA). Single-strand cDNA was synthesized using 
High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA) 
according to manufacturer's instructions. PCR amplification was performed with Thermo 
Scientific Maxima Hot Start PCR Master Mix (2X) (Thermo Scientific, Grand Island, 
NY) using 200 ng of cDNA. PCR thermal cycles were performed with Eppendorf 
Mastercycler gradient thermal cycler using the following conditions: 2 min at 94°C, 
followed by 34-38 cycles of 30 s at 95°C, 45 s at annealing Tm, and 1 min at 72°C, 
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followed by a final extension time of 10 min at 72°C. The primer pairs were designed 
with Primer-BLAST (NCBI) and synthesized by IDT (Integrated DNA Technologies, 
San Diego, CA). Sequences for each primer pair are listed in Table 1. Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) housekeeping gene was used as control.  The PCR 
products were analyzed on a 1% agarose gel by electrophoresis in the presence of 
ethidium bromide and visualized with UV light.   
 
Real-time qRT-PCR Analysis 
NK cell RNA was prepared as described previously. Target genes perforin, 
granzyme B, IFN-γ and TNF-α were quantified by real-time PCR using the CFX96 
system (Bio-Rad Laboratories, Hercules, CA). GAPDH was used as the reference gene 
for normalization. Reactions were performed in triplicate with a 25-μL mixture 
containing cDNA samples, primers, and iQ Sybr Green supermix (Bio-Rad Laboratories, 
Hercules, CA). The relative amount of mRNA in experimental cells was calculated using 
2−ΔΔCT method and CFX manager software (Bio-Rad Laboratories, Hercules, CA). 
 
Statistical Analysis 
Data are expressed as the mean ± SE (standard error) and statistical analysis were 
conducted using GraphPad Prism software v.5.01 for Windows (San Diego, CA). 
Comparisons between groups were performed using student’s t test and one-way 
ANOVA with Dunnett’s multiple comparison test, post hoc. Probability of p <0.05 was 
considered to indicate a statistically significant difference. Each experiment was repeated 
at least three times to assess the level of reproducibility. 
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Table 1. PCR primer sequences for cytokine and cytotoxic granule proteins.  
Target gene 
NCBI 
Reference 
Sequence 
Primer sequence 
Tm 
(°C) 
Amplicon 
size (bp) 
IFN-γ NM_000619.2 
Sense 5'-CTGTTACTGCCAGGACCCAT-3' 
Anti-sense 5'-GCATCTGACTCCTTTTTCGC-3' 
59 412 
TNF-α NM_000594.3 
Sense 5'-GTCCTCTTCAAGGGCCAAGG-3' 
Anti-sense 5'-CAGACTCGGCAAAGTCGAGA-3' 
57 258 
Perforin NM_005041 
Sense 5'-TGGTGGACTACACCCTGGAA-3' 
Anti-sense 5'-CACCTGGCATGATAGCGGAA-3' 
57 561 
Granzyme B NM_004131.4 
Sense 5'-GGCAGATGCAGGGGAGATCA-3' 
Anti-sense 5'-TACAGCGGGGGCTTAGTTTG-3' 
59 729 
GAPDH NM_002046.5 
Sense 5'-ACGGATTTGGTCGTATTGGGCG-3' 
Anti-sense 5'-CTCCTGGAAGATGGTGATGG-3' 
60 212 
 
Base pairs (bp), Melting temperature (Tm).  
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Results 
Isolated exosomes were evaluated for size using nanoparticle tracking analysis 
(NTA) with a NanoSight NS300 (Malvern Instruments Ltd, Malvern, UK). Mean DLCL2 
vesicle diameter was 137 nm (+/- 56 nm), with a mode of 114 nm. Mean FSCCL vesicle 
size was 156 nm (+/- 63 nm), with a mode of 128 nm (Figure 1A).  We also evaluated 
the lymphoma exosomes for several protein markers using flow cytometry and Western 
blotting. Our data showed these lymphoma vesicles did not strongly express CD63, 
LAMP-1, CD9, or TSG101. However, there was detection of MHC class I and CD81. As 
a control, protein expression from exosomes derived from normal human plasma were 
used. These plasma vesicles were positive for CD63, TSG101, HSP70, and MHC class I 
(Figure 1B and C). 
It was previously established that exosomes from an aggressive diffuse large cell 
lymphoma (WSU-DLCL2) cell line contained Survivin (Valenzuela et al., 2015). We 
wanted to confirm the presence of exosomal Survivin in WSU-FSCCL, an indolent 
follicular small cleaved cell lymphoma cell line. Western blot confirmed these B cell 
lymphoma cell lines express cellular and exosomal Survivin, in addition to other IAPs 
(Figure 2A). It was also determined that sublethal amounts of stress due to treatment 
with etoposide (0.1 µM) did not alter IAP expression levels. PCR results were 
inconsistent in what IAPs were detectable, and often negative. Housekeeping genes β-
actin and GAPDH were used as loading controls (Figure 2B). 
Survivin in the extracellular space has be previously shown to be taken up by T 
cells and elicit effects such as decreased proliferation, decreased cytolytic capabilities of 
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Figure 1.  Size and Protein Markers of Exosomes Derived from WSU-DLCL2 and WSU-
FSCCL Lymphoma Cell Lines. (A). Sizing analysis of lymphoma exosomes was 
performed with the NanoSight NS300. Mean size for exosomes was 137 nm (+/- 56 nm) 
for DLCL2 and 156 nm (+/- 63 nm) for FSCCL. (B) For analysis of expression of surface 
molecules, 200 μg of exosomes were incubated with 10 μl of 4-μm-diameter 
aldehyde/sulfate latex beads and stained with antibodies. Only the population containing 
single beads was gated and analyzed. Red = isotype, green = plasma exosomes, blue = 
DLCL2 exosomes and orange = FSCCL exosomes. (C) Mean fluorescence intensity (MFI) 
of exosome staining was compared with exosomes stained with an isotype control and 
exosomes from plasma.  
  
67 
 
Figure 2.  Lymphoma cells and exosomes contain Survivin and other IAP proteins. (A) 
Western blot showing IAPs contained in cell lysates and exosomes. Cells were treated with 
sublethal amounts of etoposide (0.1 μM) for 24 hours. GAPDH and β-actin were used as 
controls. (B) RT-PCR analysis of mRNA content in cells and exosomes. 
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CD8+ T cells, and a skewing of the cytokine profile to that of a Th2 population (Jutzy et 
al., 2013). As NK cells are frequently found to be inhibited in the TME, we investigated 
whether extracellular Survivin, or lymphoma exosomes containing Survivin, would also 
modify NK cell function.  
A well-recognized mechanism by which NK cells are inhibited in the TME is 
through interference with the activating receptor NKG2D.  Soluble and exosomal release 
of the NKG2D ligand MICA/B has been shown to reduce NKG2D expression on NK 
cells (Hedlund et al., 2011). We therefore examined whether lymphoma exosomes 
carried MICA/B (Figure 3), and if exposure to these exosomes or extracellular Survivin 
protein would alter NKG2D levels.  Analysis of exosome-coated aldehyde beads by flow 
cytometry did not detect expression of MICA/B, although the parent lymphoma cells did 
express this NKG2D ligand (Figure 3A).  Investigation of NKG2D levels on NK cells 
did not find significant changes after exposure to exosomes or Survivin, except in the NK 
cell group activated by a classical target, erythroleukemia cell line K562 (Zamai et al., 
1998). In this group there was a noticeable decrease in NKG2D levels after treatment 
with Survivin protein compared to media control (Figure 3B), although the mechanism 
by which this occurs is yet to be determined. 
To evaluate whether mechanisms other than NKG2D downregulation might be 
contributing to inhibition of NK cell function, we tested degranulation levels of NK cells 
after conditioning with Survivin or lymphoma exosomes.  Activated NK cells mobilize 
cytosolic granules containing perforin and Granzyme B to the plasma membrane for 
release, or degranulation. This process exposes the lysosomal membrane glycoproteins 
CD107a, also known as LAMP-1, which can be used as a measurement of NK cell   
69 
 
 
 
 
Figure 3.  NKG2DL are present on lymphoma cells but not exosomes, and treatment with 
Survivin protein decreases NKG2D expression. (A) Lymphoma cells express MICA/B (an 
NKG2DL), but exosomes from these two lymphoma cell lines did not.  Red = isotype, blue 
= DLCL2, orange = FSCCL. (B) NKG2D expression on NK cells (CD56+) after treatment 
with Survivin (0-1.0 μg/ml).  NK cells were activated by IL-2 (100 U/ml) and K562 target 
cells, and treated with Survivin for 24 hours. The receptor expression was assessed by mean 
fluorescence intensity (MFI) measured by fluorescent staining with NKG2D-APC 
antibody. MFI was normalized to an untreated group and data are presented as mean (± 
SEM) of three independent experiments (* is p<0.05), Survivin treatment versus untreated 
control.   
  
70 
activation or inhibition (Alter et al., 2004).  As expected, there were higher levels of 
degranulation in the NK cell group activated with IL-2, and increased degranulation in 
NK cells that were activated with PMA/Ionomycin and K562 cells. However, no 
significant changes were seen upon treatment with Survivin (Figure 4) or exosomes (data 
not shown).  
NK cell function can also be affected by the levels of its cytotoxic granule 
proteins and cytokines, as seen for example, in the TME of multiple myeloma where 
inhibition of NK cell activity occurred via lower levels of perforin and Granzyme B, 
despite unchanged degranulation (Sarkar et al., 2013).  Therefore, we next determined 
whether levels of perforin, Granzyme B, or cytokines TNF-α or IFN-γ would be affected 
by exposure of NK cells to lymphoma exosomes or Survivin protein. We treated NK cells 
with either exosomes (10 or 50 μg/ml) or Survivin protein and investigated protein levels 
by intracellular flow cytometry (Figure 5A).  Protein levels were not affected by 
activation with PMA/Ionomycin or K562 activation (data not shown). Exosomes were 
not able to exert a noticeable effect upon intracellular protein levels. However, treatment 
with extracellular Survivin protein consistently decreased protein amounts. We also used 
Western blot analysis to compare protein levels of perforin and Granzyme B in NK cells 
treated with Survivin protein (Figure 5B). 
In addition to measuring protein levels, we also investigated mRNA expression of 
perforin, Granzyme B, TNF-α and IFN-γ. We found that treatment of NK cells with 
lymphoma exosomes or extracellular Survivin for 24 hours did not result in consistent 
alterations to levels of RNA by either block RT-PCR (Figure 6A) or real time qRT-PCR 
(Figure 6C).  
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Figure 4.  Degranulation of NK cells affected by IL-2 and activation by PMA and K562, 
but not by Survivin. PBMCs from healthy donors (n=7) were treated with recombinant 
Survivin protein (0-1.0 μg/ml) with or without IL-2 for 36 hours. Degranulation activity of 
the gated CD56+ NK cell population was measured after 6 hour stimulation by PMA and 
Ionomycin, K562 target cells, or media control using flow cytometry.  Data presented as 
% of total gated NK cells that were CD107a-FITC +.  
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Figure 5.  Survivin decreases NK cell intracellular protein levels of perforin, Granzyme B, 
TNF-α and IFN-γ. (A) CD3- CD56+ NK cells were treated with extracellular Survivin 
protein or lymphoma exosomes for 24 hours. Expression of perforin, Granzyme B, TNF-α 
and IFN-γ were measured by intracellular flow cytometry (n=5). Two concentrations of 
exosomes were investigated (10 μg and 50 μg). MFI was normalized to an untreated group 
and data are presented as mean (± SEM) of five independent experiments (* is p<0.05, ** 
is p<0.01), Survivin treatment versus untreated control.   
 (B) Protein levels of NK cells after treatment with Survivin by Western blot analysis. (C) 
Densitometry by ImageJ and normalized to β-actin (n=4). 
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As a test of functionality, we investigated the cytotoxic potential of NK cells by 
measuring their ability to lyse K562 target cells. NK cells were treated with 10 μg/ml 
recombinant Survivin for 24 hours prior to performing the lactate dehydrogenase release 
assay. NK effector cells were mixed with K562 target cells at various ratios, and the 
percentage of specific lysis was calculated.  As shown in Figure 7, exposure to Survivin 
did not alter NK cell cytotoxic potential.   
 
Discussion 
The ability of tumors to avoid immune attack is critical for cancer development and 
metastasis, but the mechanisms responsible have yet to be fully elucidated. Cancer 
exosomes have emerged as mediators of immune suppression facilitating tumor survival. 
In this work, we studied the influence of lymphoma-derived exosomes and extracellular 
Survivin on NK cells. We hypothesized that tumor-derived exosomes containing Survivin 
would affect NK functionality similarly to previous findings concerning T cell 
suppression by extracellular Survivin (Jutzy et al., 2013).  Although Survivin and other 
IAPs are present in lymphoma-derived exosomes, we found little observable difference in 
NK cells functionality after exposure to these exosomes. Conversely, extracellular 
Survivin treatment did decrease NK cell intracellular protein expression of perforin, 
Granzyme B, TNF-α and IFN-γ. This is perhaps due to a concentration effect, as the 
mixed contents of exosomes may dilute or overpower the influence of Survivin delivered 
exosomally as opposed to treatment by pure protein.  While an effect on NK cell protein 
is seen with Survivin by itself, the effect is lost by dilution into exosomes. Therefore, 
Survivin in the  
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Figure 6. Lymphoma exosomes and Survivin had no consistent effect on mRNA levels of 
NK cell cytokines and granules. (A) ImageJ density analysis of block RT-PCR bands did 
not show statistical significance in mRNA levels after 24 hours treatment with lymphoma 
exosomes (10 μg and 50 μg) or Survivin (n=5). (B) Block RT-PCR amplicon products from 
NK cells from one donor run on 1% agarose gel. (C) Gene expression (ΔΔCq) was 
measured using real time qRT-PCR performed with a Bio-Rad CFX (n=5).  
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Figure 7.  Survivin treatment had no effect on NK cell cytotoxicity. NK cell cytolytic 
capacity against target K562 cells was measured via lactate dehydrogenase (LDH) release 
at serial dilutions of the effector to target (E:T) ratio from 20:1 to 0.625:1. NK effector 
cells were activated overnight with IL-2 (100 U/ml) and treated with 10 μg/ml Survivin for 
24 hours before being co-incubated with K562 cells for 4 hours.   
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TME sourced from necrosing tumor cells may show more effects than exosomal Survivin 
due either to concentration or uptake issues, as NK cells have not been shown to 
efficiently uptake exosomes (Ferguson Bennit et al., 2017). 
The lack of effects on NK cell functionality after exposure to lymphoma-derived 
exosomes could result from several factors. For example, lymphoma exosomes may not 
contain sufficient quantities of modulating proteins. Examination by Western blot and 
flow cytometry showed very low amounts of FasL, TGF-β, or MICA/B associated with 
these vesicles. There is literature support for NK cells being affected by tumor exosomes 
that harbor these proteins (Szczepanski et al., 2011). Ovarian exosomes from cell lines 
and patients have shown variable surface expression of NKG2DL (MICA/B, ULBP1-3) 
with concomitant ability to downregulate NKG2D on PBMCs, decrease degranulation, 
and inhibit cytotoxicity (Labani-Motlagh et al., 2016). Although leukemia and 
lymphoma-derived exosomes have been reported to immunosuppress cytotoxic activity 
of NK cells by binding NKG2D receptors (Hedlund et al., 2011), it is possible the EVs 
obtained from the two cell lines examined in this work are lacking key modulatory 
proteins. Actual exosome protein expression is highly dependent on the cell of origin. 
While members of the tetraspanin family CD9, CD63 and CD81 are often presented as 
“exosome markers,” this is not a binding condition.  Early studies found CD63 to be low 
in exosomes compared to cells, while CD81 was enriched ten-fold (Escola et al., 1998). 
CLL exosomes, for example, have been shown to be low in CD63 and CD81 (Paggetti et 
al., 2015), but high in CD20, HLA-DR, Hsp72 and XIAP. A study examining several B 
cell lymphoma cell lines found no CD9 expression, and variable CD63 and CD81 levels 
(Oksvold et al., 2014). Another common marker involved in exosome biogenesis is 
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TSG101, whose levels have been known to vary widely in exosomes from plasma of 
different donors, as well as to be in the lumen of exosomes (Kalra et al., 2013, Muller et 
al., 2014).  These findings highlight the importance of choosing markers for EV 
phenotyping carefully, and recognizing the diversity in exosomes from different cellular 
origins.  Characterization of the exosomes used in this study found their size to be within 
the accepted exosome range of 50-150 nm and in agreement with results from CLL 
exosomes noted to be 70-200 nm (Paggetti et al., 2015).  In this study, surface 
phenotyping revealed low CD63, CD9 and TSG101 expression, and moderate levels of 
CD81 and FasL. These lymphoma exosomes were also high in MHC class I markers, but 
had no detectable TGF-β and MICA/B. Low exosomal levels of TGF-β and MICA/B 
may partly explain the observed inability of these vesicles to decrease NKG2D 
expression on NK cells (Clayton et al., 2008, Berchem et al., 2016).  
Another factor may be found in the uptake capabilities of NK cells for these 
exosomes. Previous studies have shown that NK cells have limited capacity for EV 
internalization (Hazan-Halevy et al., 2015, Ferguson Bennit et al., 2017). However, T 
cells also exhibit low uptake ability (Muller et al., 2017) and yet are still affected by EVs 
in a variety of capacities including cytotoxicity, cytokine release, proliferation and 
activation (Whiteside, 2017).  It should also be considered that K562 target cells are Fas 
negative, so if NK cells are being modulated in their FasL expression this would not elicit 
a change in the cytotoxicity assay (Yu et al., 2009).  
While Survivin did not have a significant effect on transcripts associated with NK 
cell activity, the functional proteins were decreased, perhaps through a post translational 
mechanism. This may have an inhibitory influence on the ability of cancer-associated NK 
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cells to eliminate tumor cells. The Survivin-induced decrease in perforin and Granzyme 
B may result in granules that are less effective, even if the degranulation process itself is 
unchanged.  
Decreased cytokine levels after conditioning with extracellular Survivin may 
hinder NK cell ability to communicate with other cells in the TME. TNF-α is an 
important inflammatory cytokine for the activation of neutrophils, macrophages, and 
lymphocytes with roles in cell proliferation, differentiation, necrosis, apoptosis, and 
cytokine induction (van Horssen et al., 2006). IFN-γ has a significant anti-tumor 
influence within the TME.  It can slow the cell cycle of cancer cells, induce apoptosis, 
inhibit angiogenesis, and is a critical macrophage activating agent (Ikeda et al., 2002, 
Schroder et al., 2004).  IFN-γ upregulates MHC class I molecules to promote antigen 
presentation and immune surveillance, promotes Th1 responses, and initiates a 
chemokine directed recruitment of other immune cells (Zaidi & Merlino, 2011).  An 
essential role of NK cells in the early anti-tumor response is the rapid production of IFN-
γ. Therefore, Survivin-induced reduction of IFN-γ may contribute to the suppression 
CTL- and NK-cell–mediated immune responses central to tumor immune escape.  The 
immunomodulating effects of Survivin that reduce IFN-γ are in line with the previous T 
cell study which reported skewed immune responses away from Th1 cell-mediated 
cytotoxicity (Jutzy & Wall, 2017).  Beyond its function in cell cycle and apoptosis, 
Survivin is establishing roles in the extracellular environment of enhancing tumor 
progression and immune suppression. This interaction with the immune system is 
complex and warrants further exploration.  
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The finding that Survivin can lower important proteins for NK cell function, 
while not being able to elicit a noticeable decrease in the actual killing ability of the NK 
cells against target cells implies that Survivin in the TME may be one component in a 
multifactorial inhibition of NK cells, with other entities also involved in the crippling of 
NK cell anti-tumor responses. Thus, anti-Survivin therapies and anti-TEX therapies may 
be useful as part of a combination attack against cancer. Continuing to dissect and 
understand the contribution of exosomes to immune modulation is crucial for prevention 
of tumor escape, harnessing the patients’ own anti-tumor immune responses, and 
discovering novel therapies. 
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CHAPTER FOUR 
CONCLUSION 
TEX play a key role in tumor progression, from promoting metastatic 
characteristics, angiogenesis, niche preparation, survival, and chemoresistance (Tickner 
et al., 2014). They also exert a variety of detrimental effects on immune cells, including 
apoptosis of activated T cells, upregulation of Treg activity(Szajnik et al., 2010), 
impairment of monocyte differentiation into dendritic cells (Iero et al., 2008, Wieckowski 
et al., 2009), and accumulation of myeloid-derived suppressor cells (Xiang et al., 2009). 
Extracellular vesicles also contribute significantly to NK cell suppression via NKG2DL 
and TGF-β (Boissel et al., 2006, Szczepanski et al., 2011, Hilpert et al., 2012).  
NK cells are innate immune effector cells important in surveillance and 
destruction of cancer due to their ability to recognize and kill tumor cells in a direct way 
independent of prior sensitization and without MHC-restrictions. NKG2D is a critical 
activating receptor for anti-tumor immune surveillance (Smyth et al., 2005), and its 
stress-inducible ligands MICA/B and ULBPs are often expressed on cancer cells. Tumors 
can evade the NKG2D ligand-receptor pathway by secretion of soluble and exosomal 
NKG2DL leading to receptor inhibition (Mincheva-Nilsson & Baranov, 2014).   
NK cell suppression in the TME has been observed in many hematological 
malignancies like AML and CLL (Pierson & Miller, 1996, Costello et al., 2002, Fauriat 
et al., 2007).  Studies on exosomes and B cell lymphoma are few, especially regarding 
interactions with NK cells. Therefore it was of interest to further explore the impact of 
exosomes in lymphoma, as a more complete understanding of the underlying processes 
may pave the way to more efficacious immunological therapies against cancer. In this 
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research work, we were particularly interested in the interactions of DLCL2 lymphoma 
exosomes with peripheral blood populations.  Previous literature investigating exosome 
interactions with immune cells have reported that myeloid derived populations like 
neutrophils, monocytes, macrophages and DCs utilize multiple approaches for uptake, 
from phagocytosis to ligand binding.  B cells have also been reported to be able to bind 
and internalize exosomes from DCs or malignant cells. However, T lymphocytes and NK 
cells have not been observed to have great ability to internalize exosomes, although there 
is extensive evidence for their being affected by exosomes. It is likely that these effector 
cells are susceptible to receptor-ligand binding induced alterations, especially by FasL, 
TGF-β, PD-L1, NKG2DL. We found that uptake was most efficient in B cells and 
myeloid derived cells, with over 40% of cells being positive for exosome internalization 
after 24 hours. In comparison, T cells and NK cells were less than 10% positive for 
uptake of exosomes. These findings align with other reports of exosomal internalization 
(Hazan-Halevy et al., 2015, Muller et al., 2017).  
Analysis of lymphoma exosome protein content revealed an absence of TGF-β 
and MICA/B, and the presence of FasL and Survivin.  Extracellular Survivin has been 
previously found to interact with T cell populations to promote a cancer permissive 
environment through inhibition of CD8+ T cell function and proliferation, as well 
skewing the cytokine profile to that of a Th2 surveillance response instead of a cytotoxic 
one (Jutzy et al., 2013). Therefore, we investigated what contribution Survivin may have 
in the NK cell modifications frequently observed in tumor settings.  Treatment with 
recombinant Survivin protein was able to decrease NKG2D receptor levels in NK cells 
stimulated with target cells, and decrease protein levels of TNF-α, IFN-γ, perforin, and 
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Granzyme B.  Exposure of NK cells to lymphoma exosomes did not result in observable 
changes in degranulation, cytotoxic ability, or protein and mRNA levels of perforin, 
Granzyme B, and cytokines. The findings of this work contribute to a better knowledge 
of the repertoire of lymphoma exosomal contents and their potential immune modulating 
contributions. This may open new possibilities for the use of NK cells in immunotherapy 
against lymphoma and other hematological malignancies.  
Although recent advances in cancer immunotherapies have ignited much 
enthusiasm and hope for patients and oncologists, therapeutic outcomes are often 
disappointing in many clinical trials. Cancer cell modulation of the TME is a critical 
factor in switching from a tumor-destructive environment to a tumor-promoting one that 
favors immunosuppressive immune cell populations such as MDSCs and Tregs.  Immune 
cells capable of anti-tumor actions such as NK cells and T cells are frequently inhibited. 
TME mechanisms that impair NK cell anti-tumor function are detrimental to the success 
of monoclonal antibody immunotherapies that depend on NK-mediated killing strategies.  
As exosomes play a significant role in NK cell suppression, further research on the 
exosomes derived from B cell lymphoma was warranted. The findings of this work 
contribute to a better knowledge of the repertoire of exosomal contents and their potential 
immune modulating contributions. This will open new possibilities for the use of NK 
cells in immunotherapy against lymphoma and other hematological malignancies.  
The future directions of this project include looking at changes in the proteome 
and transcriptome of NK cells upon conditioning with Survivin and lymphoma exosomes. 
These arrays would give a wider view of the extent of changes that occur when NK cells 
in the TME are exposed to lymphoma derived exosomes and extracellular Survivin, as 
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well as elucidate pathways and mechanisms utilized by Survivin to elicit the decreases in 
NK cell proteins. A further characterization of lymphoma exosomes from cell lines and 
patient samples might also reveal significant information as to the mechanism of immune 
suppression in this disease.  As this study used NK cells from healthy donors, who had a 
wide degree of variability in their immune status and NK cell responses, it might also be 
helpful to repeat some experiments, particularly the mRNA investigations, with an NK 
cell line such as NK92. Additionally, we would like to explore the effects of extracellular 
Survivin on other cell populations in the TME, such as DCs and monocytes.  
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Investigated the effects oral administration of turmeric had on in vitro T cell 
proliferation rates of mice splenocytes, specifically T cells post stimulation with 
mitogen.  
 
Publications 
Manuscripts 
Khan S, Ferguson Bennit H, Turay D, Perez M, Mirshahidi S, Yuan Y, Wall NR. Early 
diagnostic value of Survivin and its alternative splice variants in breast cancer.  BMC 
Cancer. 2014;14:176. 
Khan S, Ferguson Bennit H, Wall NR. The emerging role of exosomes in survivin 
secretion. Histol Histopathol. 2015 (30); 43-50. Review.  
Khan S, Ferguson Bennit H, Valenzuela MMA, Turay D, Diaz Osterman CJ, Moyron 
RB, Esebanmen GE, Ashok A, Wall NR. Localization and up regulation of Survivin in 
cancer health disparities: a clinical perspective. Biologics: Targets and Therapy, 9:57-67, 
2015. Review 
Valenzuela MMA, Ferguson Bennit H, Gonda A, Diaz Osterman CJ, Hibma A, Khan S, 
Wall NR. Exosomes secreted from human cancer cell lines contain inhibitors of apoptosis 
(IAP).  Cancer Microenvironment, 8(2):65-73, 2015.  
Diaz Osterman CJ, Lynch JC, Leaf P, Gonda A, Ferguson Bennit H, Griffiths D, Wall 
NR. Curcumin Modulates pancreatic adenocarcinoma cell-derived exosomal function. 
PLoS One, 10(7), 2015. 
Diaz Osterman CJ, Gonda A, Stiff TR, Sigaran U, Valenzuela MMA, Ferguson Bennit 
H,  Moyron RB, Khan S, Wall NR. Curcumin Induces Pancreatic Adenocarcinoma Cell 
Death via Reduction of the Inhibitors of Apoptosis. Pancreas. 2016; 45(1):101-109.  
Ferguson Bennit H, Gonda A, Oppegard LJ, Chi DP, Khan S, Wall NR. Uptake of 
lymphoma-derived exosomes by peripheral blood leukocytes. Blood and Lymphatic 
Cancer: Targets and Therapy, 7:9-23, 2017.  
 
Abstracts 
Ferguson Bennit H, Gonda A, Chi D, Oppegard L, Licero J, De Leon M, Khan S, Wall 
NR. Effects of Survivin and lymphoma cell-derived exosomes on natural killer cell 
function. AACR Special Conference: The Function of Tumor Microenvironment in 
Cancer Progression, San Diego, January 2016 
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Ferguson Bennit H, Valenzuela MMA, Jutzy JMS, Khan S, Wall NR. B-cell lymphoma 
derived exosomes are reservoirs of Inhibitors of Apoptosis. AACR, April 2014 
Ferguson Bennit H, Valenzuela MMA, Wall NR. Survivin is released from B-cell 
lymphomas through exosomes. NSRF April 2012 
Diaz-Osterman CJ, Ferguson HR, Valenzuela MMA, Khan S, Wall NR. Curcumin 
suppresses pancreatic cancer growth by targeting survivin. Gordon Conference, 2013. 
Diaz-Osterman C, Ferguson HR, Valenzuela MMA, Khan S, Wall NR. 6-gingerol and 
curcumin suppress pancreatic cancer growth by targeting the inhibitors of apoptosis. 
AACR Conference on Pancreatic Cancer: Progress and Challenges, June 2012 
Sigaran U, Diaz Osterman CJ, Stiff TR, Ferguson HR, Valenzuela MMA, Khan S, Wall 
NR.  Curcumin induces pancreatic cancer cell death by targeting the inhibitor of 
apoptosis proteins. 13th Annual Health Disparities Research Symposium, August 7, 2013, 
Loma Linda University. 
Diaz-Osterman C, Ferguson H, Valenzuela MMA, Khan S, Wall NR. 6-gingerol and 
curcumin suppress pancreatic cancer growth by targeting the inhibitors of apoptosis. 
Fifteenth Annual Basic Sciences Research Symposium, October 29, 2012, Loma Linda 
University. 
 
Public Presentations 
Poster presentation at AACR TME conference, San Diego 2016 
Poster presentation at Southern California Flow Cytometry Summit, Irvine CA 2015 
Oral presentation at CHDMM Chalk Talk, March 2014 
Poster Presentation at AACR National meeting, San Diego (2014) 
Poster presentation at Annual Postgraduate Conference, Loma Linda University (2013, 
2015) 
Poster presentation for Annual Basic Sciences Research Symposium, Loma Linda 
University (2011, 2012) 
Poster presentation at National Student’s Research Forum at UTMB, Galveston TX 
(2012) 
Presented poster of research results for faculty and students at University of California, 
Riverside (2009) 
Presented poster at Murdock Conference 2009 in Spokane, WA 
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Manuscripts in Preparation 
Ferguson Bennit HR, Gonda A, McMullen JR, Kabagwira J, Wall NR. Peripheral blood 
cell interaction of cancer-derived exosomes affect immune function. (Review) 
Ferguson Bennit HR, Gonda A, Oppegard L, Chi David, Licero J, Asuncion Valenzuela 
MM, Jutzy JMS, De Leon M, Khan S, Wall NR. Natural killer cell phenotype and 
functionality affected by exposure to extracellular Survivin and lymphoma-derived 
exosomes.  
Nicholas D, Garcia-Perez D, Sorensen D, Ferguson Bennit H, Langridge W, De Leon 
M. Fatty acids, inflammation, and type 2 diabetes. Review 
 
Mentorship Experiences 
Research Mentor 
Laura Oppegard, 1st year Medical student (2015) 
David Chi, 1st year Medical student (2015) 
James McMullen, 1st year PhD student (2015) 
Abby Hibma, 2nd year medical student (2013) 
Amber Gonda, 2nd year PhD student (2013) 
Ron Moyron, 1st year PhD student (2013) 
Naomi Jackson, 1st year PhD student, Big Brother/Big Sister program 2013-2014 
Sonia Whang, 1st year PhD student (2012) 
 
Professional Memberships 
2012-2017 American Association for Cancer Research (AACR) 
2010-2017 American Physician Scientist Association (APSA) 
2011-2017 Southern California Flow Cytometry Association 
2015-2017 International Society for Extracellular Vesicles (ISEV) 
2014-2017 American Society of Clinical Oncology (ASCO) 
2007-2010 Engineers Without Borders (EWB) 
2006-2010 Society of Women Engineers (SWE) 
 
110 
Volunteer and Leadership Experiences 
2017-2018 School of Medicine Class of 2020 Senator  
2016  Interviewer for potential participants of ABC Summer Research Program 
2014-2015 MD/PhD Representative for Basic Science Student Council  
2014 Treasurer for St Baldrick’s Foundation for Pediatric Cancer Event, Loma 
Linda University  
2013  Basic Science Symposium Steering Committee, Student Representative 
2012-2014 Academic Affairs Vice President for Basic Science Student Council 
2011-2012 Secretary for Basic Sciences Student Council 
2006-2009 Secretary of local chapter of Engineers Without Borders 
 
Honors 
2010-2015  Graduate Student Stipend Award 
2013  Dean’s Award for Excellence for Best Written Comprehensive Exam 
2010  Completed Bachelor of Science with summa cum laude honors 
2006-2009 Dean’s List of Distinguished Students (GPA over 3.75) every quarter  
2006  James R. Hoffa Memorial Scholarship 
2006  High School Valedictorian 
 
